Literature DB >> 35415372

M1 Macrophages Enhance Survival and Invasion of Oral Squamous Cell Carcinoma by Inducing GDF15-Mediated ErbB2 Phosphorylation.

Chunxu Lv1, Shutong Li1, Jingjing Zhao1, Pishan Yang1, Chengzhe Yang2.   

Abstract

M2 macrophages are generally recognized to have a protumor role, while the effect of M1 macrophages in cancer is controversial. Here, the in vitro and in vivo effects of conditioned medium from M1 macrophages (M1-CM) on oral squamous cell carcinoma (OSCC) cells and a potential mechanism were studied. CCK-8, colony formation, EdU labeling, xenograft growth, and Transwell assays were utilized to observe cell survival/proliferation and migration/invasion, respectively, in OSCC cell lines treated with basic medium (BM) and M1-CM. The ErbB2 phosphorylation inhibitor (CI-1033) and GDF15 knockout cell lines were used to appraise the role of ErbB2 and GDF15 in mediating the effects of M1-CM. Compared with BM, M1-CM significantly enhanced the survival/proliferation of SCC25 cells. The migration/invasion of SCC25 and CAL27 cells also increased. Mechanically, M1-CM promoted GDF15 expression and increased the phosphorylation of ErbB2, AKT, and ErK. CI-1033 significantly declined the M1-CM-induced activation of p-AKT and p-ErK and its protumor effects. M1-CM stimulated enhancement of p-ErbB2 expression was significantly decreased in cells with GDF15 gene knockout vs without. In xenograft, M1-CM pretreatment significantly promoted the carcinogenic potential of OSCC cells. Our results demonstrate that M1 macrophages induce the proliferation, migration, invasion, and xenograft development of OSCC cells. Mechanistically, this protumor effect of M1 macrophages is partly associated with inducing GDF15-mediated ErbB2 phosphorylation.
© 2022 The Authors. Published by American Chemical Society.

Entities:  

Year:  2022        PMID: 35415372      PMCID: PMC8992263          DOI: 10.1021/acsomega.2c00571

Source DB:  PubMed          Journal:  ACS Omega        ISSN: 2470-1343


Introduction

Oral squamous cell carcinoma (OSCC) is the most common type of head and neck tumor. Like other cancers, research on OSCC has emphasized the potential role of the tumor microenvironment (TME) in tumor progression and metastasis. The TME comprises many kinds of cells, among which tumor-associated macrophages (TAMs) are essential and abundant cell types.[1,2] TAMs possess M1-like and M2-like phenotypes.[3] M1 macrophage differentiation is induced with lipopolysaccharide (LPS) and/or interferon-γ. It is characterized by increased expression of specific proinflammatory cytokines, for instance, TNF-α, IL-6, IL-1β, and IL-12, and is responsible for eliminating pathogens and tumor cells. The differentiation of M2 macrophage is promoted by IL-4 and/or IL-13 and is characterized by anti-inflammatory and protumor effects mediated by the inhibition of the immune response.[4,5] M1 macrophages can be identified by the expression of CD80 or CD86, while M2 macrophages specifically express CD163 or CD206.[6] It is well recognized that M2 macrophages contribute to tumor progression and metastasis via immunosuppressive, pro-angiogenic, and cell-invasive function.[7,8] However, the role of M1 macrophages in cancers remains controversial. Although the accumulating evidence shows its anticancer potential,[9,10] M1 macrophages have also been reported to have the effect of promoting cancer cell metastasis and proliferation.[11,12] Therefore, further study of the role of M1 macrophages in cancers and the underlying mechanisms is required. ErbB2 (HER-2/neu) is a transmembrane receptor of EGFR, has intrinsic tyrosine kinase activity, and can interact with many different cellular proteins, such as growth differentiation factor 15 (GDF15),[13,14] and it affects cell proliferation, metastasis, and angiogenesis through MAPK and PI3K/AKT pathway activation.[15] Moreover, mounting evidence show that the ErbB2 receptor is activated in OSCC cells.[16−18] GDF15 belongs to a branch member of the TGF-β superfamily. Its expression is affected by inflammation, injury, and malignant tumors. High expression of GDF15 is related to the poor clinical outcomes in colorectal cancer and prostate pancreatic cancer.[19,20] Our previous study also reveals that GDF15 promotes the occurrence and progression of OSCC.[21] It has also been reported that GDF15 induces Src-dependent ErbB2 phosphorylation.[13,14] However, whether GDF15/ErbB2 is involved in the effect of M1 macrophages on OSCC has not been studied. In this study, the effect of M1 macrophages on the proliferation, migration, and invasion of OSCC cell lines in vitro and xenograft growth in vivo was studied. We also evaluated the role of GDF15/ErbB2 and its downstream signaling pathways in this process.

Results

Monocytes Differentiate into Pro-inflammatory M1Macrophages

To simulate the inflammatory tumor microenvironment, LPS (200 ng/mL) was used to stimulate M0 macrophages for 48 h, and then the phenotype of proinflammatory M1 macrophages was first identified. CD80 and CD86 were obviously upregulated at the gene and protein levels in M1 macrophages (Figure a,b). Furthermore, we confirmed that LPS could significantly increase the level of TNF-α and IL-6 (Figure c,d), which have been recognized as the main factors secreted by M1 macrophages at the gene and protein levels.
Figure 1

LPS induce M1 macrophage polarization. M0 macrophages were incubated with LPS for 48 h with unstimulated M0 cells as the control (NC). (a) mRNA level of CD80 and CD86 in macrophages stimulated with or without LPS. (b) Protein level of CD80 and CD86 in macrophages stimulated with or without LPS (up panel); quantitative analysis of CD80 and CD86 expression (down panel). (c) mRNA level of TNF-α and IL-6 in macrophages stimulated with or without LPS. (d) Protein secretion into the culture medium was measured by ELISA. The results are expressed as the mean ± SD (n = 3). *** p < 0.001.

LPS induce M1 macrophage polarization. M0 macrophages were incubated with LPS for 48 h with unstimulated M0 cells as the control (NC). (a) mRNA level of CD80 and CD86 in macrophages stimulated with or without LPS. (b) Protein level of CD80 and CD86 in macrophages stimulated with or without LPS (up panel); quantitative analysis of CD80 and CD86 expression (down panel). (c) mRNA level of TNF-α and IL-6 in macrophages stimulated with or without LPS. (d) Protein secretion into the culture medium was measured by ELISA. The results are expressed as the mean ± SD (n = 3). *** p < 0.001.

M1-CM Significantly Enhances OSCC Proliferation, Migration, and Invasion In Vitro

To evaluate the effects of factors secreted by M1 macrophages on the biological behaviors of OSCC, we assessed the effect of conditioned medium from M1 macrophages (M1-CM, containing 50% M1 macrophage culture supernatant +50% basic medium) on SCC25 and CAL27 cells with basic medium (BM) as the control. CCK-8 (Figure a), colony formation (Figure b), and EdU assay (Figure c) showed that M1-CM significantly increased SCC25 cell proliferation vs BM but did not for CAL27 cells (data not shown). Additionally, the flow cytometry analysis results indicated no significant effect of M1-CM on SCC25 and CAL27 cell apoptosis (Figure d). Transwell assays showed that, compared with BM, M1-CM significantly increased the migration and invasion abilities of SCC25 and CAL27 cells at 24 h (Figures e,f). These data indicate that in vitro M1-CM promotes proliferation, migration, and invasion of OSCC cells.
Figure 2

Effects of M1-CM on OSCC cell proliferation, migration, and invasion. (a) Growth curvature of SCC25 cells cultured in BM and M1-CM from 1 to 6 d. (b) colony formation assay of SCC25 cells cultured in BM and M1-CM for 7 d (left panel); statistical results of cell colony formation by SCC25 cells (n = 6, right panel). (c) EdU assay of SCC25 cells cultured in BM and M1-CM for 48 h. Scale bar: 50 μm (left panel); statistical analysis (n = 6, right panel). (d) Detection of the apoptosis rate of SCC25 and CAL27 cells cultured with BM and M1-CM for 48 h (left panel); statistical analysis of apoptosis based on the left panel (n = 3). Migration and invasion pictures of SCC25 (e) and CAL27 cells (f). Scale bars = 100 μm (left panel); quantitative analysis of SCC25 and CAL27 cell migration and invasion (n = 3, right panel). BM, normal DMEM medium; and M1-CM, 50% M1 macrophage culture supernatant and 50% basic medium. Results are expressed as the mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001.

Effects of M1-CM on OSCC cell proliferation, migration, and invasion. (a) Growth curvature of SCC25 cells cultured in BM and M1-CM from 1 to 6 d. (b) colony formation assay of SCC25 cells cultured in BM and M1-CM for 7 d (left panel); statistical results of cell colony formation by SCC25 cells (n = 6, right panel). (c) EdU assay of SCC25 cells cultured in BM and M1-CM for 48 h. Scale bar: 50 μm (left panel); statistical analysis (n = 6, right panel). (d) Detection of the apoptosis rate of SCC25 and CAL27 cells cultured with BM and M1-CM for 48 h (left panel); statistical analysis of apoptosis based on the left panel (n = 3). Migration and invasion pictures of SCC25 (e) and CAL27 cells (f). Scale bars = 100 μm (left panel); quantitative analysis of SCC25 and CAL27 cell migration and invasion (n = 3, right panel). BM, normal DMEM medium; and M1-CM, 50% M1 macrophage culture supernatant and 50% basic medium. Results are expressed as the mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001.

M1-CM Enhanced Proliferation, Migration, and Invasion of OSCC Cells Are Associated with ErbB2/PI3K/AKT and MAPK/ErK Signaling Pathways

The PI3K/AKT and MAPK/ErK signaling pathways play key roles in regulating cell growth, migration, and invasion, while ErbB2 affects cell proliferation, metastasis, and angiogenesis through MAPK/ErK and PI3K/AKT pathway activation.[17−19] To observe whether ErbB2/PI3K/AKT and MAPK/ErK signaling pathways are associated with M1-CM enhanced proliferation, migration, and invasion, the effect of M1-CM on phosphorylation of AKT, ErK, and ErbB2 of OSCC cells was studied. Our study confirmed that M1-CM activated the AKT and ErK by increasing the protein level of p-AKT and p-ErK in SCC25 and CAL27 cells with peak levels at 30 min (Figure a). M1-CM also significantly promoted the phosphorylation of ErbB2 (Figure b). To elucidate whether M1-CM-activated AKT and ErK signaling pathways are associated with the ErbB2 receptor, the ErbB2 inhibitor CI-1033 was used.[22,23] CI-1033 significantly decreased M1-CM-induced p-AKT and p-ErK expression in SCC25 and CAL27 cells (Figure c). Finally, to explore whether the ErbB2 receptor is also involved in promoting OSCC proliferation, migration, and invasion by M1-CM, SCC25 and CAL27 cells were pretreated with the inhibitor for 2 h and then stimulated with M1-CM. The results showed that the inhibitor significantly inhibited M1-CM induced SCC25 cell proliferation (Figures a,b) and decreased the M1-CM-promoted SCC25 and CAL27 cell migration and invasion (Figure c,d). These results indicate that M1-CM-enhanced proliferation, migration, and invasion are associated with ErbB2/PI3K/AKT and MAPK/ErK signaling pathways.
Figure 3

Effects of M1-CM on ErbB2/AKT/ErK signaling pathway activation. (a) The protein levels of ErK, p-ErK, AKT, and p-AKT in SCC25 and CAL27 cells stimulated by M1-CM. The relative expressions of p-ErK/ErK and p-AKT/AKT were detected (n = 3). (b) Protein level of ErbB2 and p-ErbB2 in SCC25 and CAL27 cells (up panel) treated with or without M1-CM for 30 min; quantitative analysis of p-ErbB2/ErbB2 protein expression (down panel). (c) Protein expression of ErK, p-ErK, AKT, and p-AKT in SCC25 and CAL27 cells treated with or without M1-CM and Inhibitor + M1-CM (left panel); quantitative analysis of p-ErK/ErK and p-AKT/AKT (right panel) expression. The histograms represent the mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001.

Figure 4

Effects of an ErbB2 receptor inhibitor on M1-CM induce cell proliferation, migration, and invasion. (a) SCC25 cells were cultured in the BM, M1-CM, and inhibitor + M1-CM from 1 to 6 d, and the growth curvature was detected by CCK-8 assay. (b) SCC25 cells were cultured for 24 h in the BM, M1-CM, and inhibitor+M1-CM, and then the proliferation ability was examined by EdU assay. (c) SCC25 cells were cultured in the BM, M1-CM, and inhibitor+M1-CM. The migration and invasion of SCC25 cells were evaluated by Transwell assays (left panel); the statistical analysis of migration and invasion rates (right panel). (d) CAL27 cells were cultured in BM, M1-CM, and inhibitor+M1-CM. The migration and invasion of CAL27 cells were detected by Transwell assays (left panel); statistical analysis of the migration and invasion rates (right panel). The histograms represent the mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001.

Effects of M1-CM on ErbB2/AKT/ErK signaling pathway activation. (a) The protein levels of ErK, p-ErK, AKT, and p-AKT in SCC25 and CAL27 cells stimulated by M1-CM. The relative expressions of p-ErK/ErK and p-AKT/AKT were detected (n = 3). (b) Protein level of ErbB2 and p-ErbB2 in SCC25 and CAL27 cells (up panel) treated with or without M1-CM for 30 min; quantitative analysis of p-ErbB2/ErbB2 protein expression (down panel). (c) Protein expression of ErK, p-ErK, AKT, and p-AKT in SCC25 and CAL27 cells treated with or without M1-CM and Inhibitor + M1-CM (left panel); quantitative analysis of p-ErK/ErK and p-AKT/AKT (right panel) expression. The histograms represent the mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001. Effects of an ErbB2 receptor inhibitor on M1-CM induce cell proliferation, migration, and invasion. (a) SCC25 cells were cultured in the BM, M1-CM, and inhibitor + M1-CM from 1 to 6 d, and the growth curvature was detected by CCK-8 assay. (b) SCC25 cells were cultured for 24 h in the BM, M1-CM, and inhibitor+M1-CM, and then the proliferation ability was examined by EdU assay. (c) SCC25 cells were cultured in the BM, M1-CM, and inhibitor+M1-CM. The migration and invasion of SCC25 cells were evaluated by Transwell assays (left panel); the statistical analysis of migration and invasion rates (right panel). (d) CAL27 cells were cultured in BM, M1-CM, and inhibitor+M1-CM. The migration and invasion of CAL27 cells were detected by Transwell assays (left panel); statistical analysis of the migration and invasion rates (right panel). The histograms represent the mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001.

M1-CM Activates the ErbB2 Signaling Pathway via GDF15

GDF15 has been reported to induce Src-dependent phosphorylation of ErbB2 in human breast cancer and stomach cancer cells.[14,24] This pushes us to study whether GDF15 mediates M1-CM-induced ErbB2 phosphorylation in OSCC cells. We demonstrated that GDF15 gene and protein expression and secretion were significantly promoted by M1-CM vs BM control (Figure a–c). After the GDF15 gene was knocked out (Figure d,e), p-ErbB2 expression was significantly decreased compared with cells transfected with negative vector no matter with or without M1-CM stimulation (Figures f,g), suggesting that GDF15 is partly involved in the M1-CM-stimulated activation of the ErbB2.
Figure 5

M1-CM-enhanced GDF15 expression mediates ErbB2 phosphorylation. (a) Gene expression of GDF15. (b) Protein expression of GDF15 (left panel); quantitative analysis of GDF15 protein expression (right panel). (c) Protein expression of GDF15 in the supernatant was examined by ELISA. (d) SCC25 and CAL27 cells transfected with negative vector or GDF15 lentivirus were observed. (e) Protein level of GDF15 was detected by Western blotting (left panel); quantitative analysis of GDF15 expression (right panel). (f, g) Protein level of ErbB2 and p-ErbB2 in SCC25 and CAL27 cells was assessed respectively by Western blotting (left panel); quantitative analysis of p-ErbB2/ErbB2 expression (right panel). The histograms represent the mean ± SD (n = 3). **p < 0.01 and ***p < 0.001.

M1-CM-enhanced GDF15 expression mediates ErbB2 phosphorylation. (a) Gene expression of GDF15. (b) Protein expression of GDF15 (left panel); quantitative analysis of GDF15 protein expression (right panel). (c) Protein expression of GDF15 in the supernatant was examined by ELISA. (d) SCC25 and CAL27 cells transfected with negative vector or GDF15 lentivirus were observed. (e) Protein level of GDF15 was detected by Western blotting (left panel); quantitative analysis of GDF15 expression (right panel). (f, g) Protein level of ErbB2 and p-ErbB2 in SCC25 and CAL27 cells was assessed respectively by Western blotting (left panel); quantitative analysis of p-ErbB2/ErbB2 expression (right panel). The histograms represent the mean ± SD (n = 3). **p < 0.01 and ***p < 0.001.

M1-CM Promotes Tumor Formation In Vivo

Twelve nude mice (six mice in each group) were subcutaneously transplanted with SCC25 cells and M1-CM induced SCC25 cells to evaluate the tumorigenesis ability of M1-CM (Figure a). The xenograft assay showed that M1-CM induced SCC25 cells formed much larger tumors in terms of volume (Figure b) and weight (Figure c) than SCC25 cells. Furthermore, IHC revealed that the Ki67-positive cells in SCC25 cells induced by M1-CM were markedly higher (Figure d). The results indicate that M1-CM promotes tumor formation in vivo.
Figure 6

M1-CM promoted tumor formation in vivo. (a) Pictures showing the tumor size of nude mice from SCC25 cells and M1-CM-stimulated SCC25 cells. Tumor growth curvature (b) and tumor weights (c) are shown for SCC25 cells and M1-CM-stimulated SCC25 cells. (d) Immuno-histochemical staining results for Ki67; statistical analysis revealed significantly greater numbers of Ki67 positive (p < 0.001) in M1-CM-stimulated SCC25 cells than SCC25 cells. The histograms represent the mean ± SD (n = 6). *p < 0.05, **p < 0.01, and ***p < 0.001.

M1-CM promoted tumor formation in vivo. (a) Pictures showing the tumor size of nude mice from SCC25 cells and M1-CM-stimulated SCC25 cells. Tumor growth curvature (b) and tumor weights (c) are shown for SCC25 cells and M1-CM-stimulated SCC25 cells. (d) Immuno-histochemical staining results for Ki67; statistical analysis revealed significantly greater numbers of Ki67 positive (p < 0.001) in M1-CM-stimulated SCC25 cells than SCC25 cells. The histograms represent the mean ± SD (n = 6). *p < 0.05, **p < 0.01, and ***p < 0.001.

Discussion

The tumor-supportive role of M2-macrophages is generally accepted, but the role of M1 macrophages in cancers remains controversial. For the first time, this study demonstrated that M1 macrophages potentiate proliferation, migration, and invasion got in vitro and in vivo xenograft formation of OSCC cells. More interesting, we found the novel mechanism by which M1 macrophages potentiate the proliferation, migration, and invasion of OSCC cells, namely, via GDF15-mediated ErbB2 phosphorylation. Cancer cells secrete inflammatory chemokines to recruit monocytes/macrophages to the inflamed TME and activate residential macrophages in tissues, thus generating a TAM population. On the other hand, TAMs secrete several cytokines, chemokines, growth factors, and inflammatory mediators that possess cytotoxic and tumoricidal activities or exert anti-inflammatory and tumor-supportive effects. Although the M2-like phenotype, which has a tumor-promoting effect, is dominant in TAMs and skewing the M1/M2 ratio toward the M1 phenotype can inhibit tumor growth, TAMs phenotypes are a mixture of M1-like and M2-like phenotypes, and the protumor role of M1 macrophages has also been demonstrated in many studies. TNF has been proved to promote angiogenesis and metastasis of OSCC cells as well as in several models in vivo. At the same time, M1 macrophages are the primary sources of TNF in the TME.[25] More recently, Zong et al. showed that M1 macrophages induce the level of PD-L1 in hepatocellular carcinoma cells (HCC), supporting the protumor role of M1 macrophages.[26] Helm et al. revealed that M1 macrophages contribute to EMT in premalignant and malignant pancreatic ductal epithelial cells.[27] Guo et al. demonstrated that M1 macrophages induce the development of breast cancer stem cell (CSC)-like phenotypes.[28] We used LPS to activate the macrophages to classic M1 phenotype in vitro study.[29,30] Although a few M2 macrophages were recognized by the expression of CD163 and CD206, M1 macrophages were still the majority of this population (Figure S1). Consistent with other studies, our present study demonstrated that M1 macrophages potentiate in vitro proliferation, migration, and invasion and in vivo xenograft formation of OSCC cells. Given the tumor-supportive effect of M1 macrophages, the underlying mechanisms need to be explored. Several clinical studies have indicated that high serum concentrations of proinflammatory cytokines are related to poor prognosis in many types of malignancies. Elevated levels of IL-6 in the tumor microenvironment are well-known to be involved in metastasis and cell survival.[31] TNF-α mediates cancer progression in various cancer types through NF-κB activation. Our observations are consistent with previous reports showing that M1-CM contains a high potency of IL-6 and TNF-α, suggesting that paracrine of proinflammatory cytokines are, at least in part, associated with the tumor-supportive effect of M1 macrophages.[28,32] The PI3K/AKT and MAPK/ErK signaling pathways play critical roles in regulating cell growth, migration, and invasion. At the same time, GDF15 has been demonstrated to stimulate ErbB2, AKT, and ErK in human breast and stomach cancer cells in vitro.[14,22] Moreover, the ErbB2 receptor is activated in OSCC.[16−18] The present study confirmed that in OSCC, M1-CM activated the AKT and ErK signaling pathways. Moreover, the ErbB2 receptor was also activated, and CI-1033 significantly decreased M1-CM-induced p-AKT and p-ErK expression and proliferation, migration, and invasion; these findings indicate that M1-CM activates the PI3K/AKT and MAPK/ErK signaling pathways in part by activating the ErbB2 receptor. GDF15 plays an important role in promoting the development of OSCC and other tumors.[21,33,34] It has been reported that GDF15 expression is induced by inflammatory conditions.[35] However, whether GDF15 expression is regulated by TAMs has not been reported. Our results confirmed that M1-CM enhanced the secretion and expression of GDF15 in OSCC cells and that GDF15 knockout inhibited M1-CM-induced phosphorylation of ErbB2. However, as shown in Figure f,g, p-ErbB2 expression was still increased by M1-CM stimulation after GDF15 was knocked out. These seem to indicate that GDF15 plays a partial role in M1-CM enhanced p-ErbB2 expression. Indeed, the other ligands can activate EGFR receptors, including ErbB2.[36] The tumor-supportive role of M2 macrophages is generally accepted, but both pro- and antitumor functions of M1 macrophages have been reported. This paradox of M1 macrophages may be related to, but not limited to, the following factors: (1) heterogeneity among cancers originated from various tissues and (2) cell-type specificity: in our study, M1 macrophages exerted differential effects on SCC25 and CAL27 cells. M1-CM promoted proliferation of SCC25, a tongue squamous cell carcinoma cell line, but had no such effect on CAL27, a type of tongue adenosquamous carcinoma cell line. (3) Numbers of M1 macrophages: there is a notion that a lower number of M1 macrophages promotes xenograft development, while a larger number of M1 macrophages reduce xenograft development.[37] In our in vivo supplementary experiment, we coinoculated a small number of M1 macrophages (1 × 105) and a larger number of SCC25 cells (5 × 106) into nude mice. The results showed that tumor size and volume formed by this coinoculation were significantly larger than those of SCC25 cells inoculated alone (Figure S2).

Conclusions

Taken together, our preliminary results indicate that M1 macrophages contribute to the proliferation, migration, and invasion and xenograft development of OSCC cells partly by inducing GDF15-mediated ErbB2 activation. However, more and deeper studies are needed to evaluate the paradoxical role of M1 macrophages in OSCC. In this regard, the effect of M1 macrophages on the immune cells, especially CD8+ T-cell, is an important aspect. The model of coculture of M1 macrophages and tumor cells in different proportions in vitro is also helpful to comprehensively evaluate the role of M1 macrophages in OSCC.

Materials and Methods

Cells Culture and M1-Macrophage Polarization

Human monocytic THP-1 cells (Stem Cell Bank, Chinese Academy of Sciences) were cultured in RPMI 1640 medium (Hyclone, Logan, UT) containing 10% fetal bovine serum (FBS, Bioind, Kibbutz Beit Haemek, Israel) and 50 pM β-mercaptoethanol (Gibco; Grand Island, NY). THP-1 cells were differentiated into macrophages (M0) by incubation with 100 ng/mL phorbol 12- myristate 13-acetate (PMA, Sigma, St. Louis, MO) for 24 h, and the adherent cells were washed with PBS to remove the remaining PMA. The macrophages were polarized toward the M1 phenotype by incubation with 200 ng/mL Porphyromonas gingivalis LPS (InvivoGen, San Diego, CA) for 48 h. Polarized M1 macrophages were characterized by CD80 or CD86 expression. After 48 h of polarization, the polarizing stimulator LPS was removed by aspirating culture supernatants, and a fresh culture medium was added for a further 48 h incubation. Then the culture supernatants were centrifuged for later use. The human OSCC cell lines CAL27 and SCC25 (ATCC, Manassas, VA) were maintained in a DMEM medium (Hyclone) containing 10% FBS. All of the cells were cultured in a humidified environment with 5% CO2 at 37 °C.

Generation of GDF15 Knockout Stable Cell Lines

Single-guide RNAs (sgRNAs) were used to generate CRISPR-Cas9-based GDF15 knockout constructs (sgGDF15#1 forward, 5′-GAAACTTGCGCGGCTCGCCT-3′, reverse, 5′-AGGCGAGCCGCGCAAGTTTC-3′). The sgGDF15 plasmid was transiently transfected into the OSCC cells. Puromycin (1 μg/mL) was added to the medium, and the cells remained for 2 weeks for single clone selection. The GDF15 knockout efficacy was determined by Western blotting.

Cell Proliferation Assay

After being cultured with BM or M1-CM, the cell proliferation was evaluated by CCK-8 (Dojindo Laboratories, Kumamoto, Japan). After incubation for 1.5 h, absorbance at 450 nm wavelength was measured.

Colony Generation Assay

SCC25 cells were cultivated with BM or M1-CM for 7 d. Then the cells were treated using the protocol described in a previously.[38]

EdU Assay

SCC25 cells were cultured with BM or M1-CM for 24 h. Then the supernatant was discarded and the EdU labeling assay was performed according to the procedures described previously.[38]

Cell Apoptosis Analysis by Flow Cytometry

SCC25 and CAL27 cells were cultured with BM or M1-CM for 2 days. Then the cells were treated using the protocol outlined in a previously.[38]

Transwell Assays

SCC25 and CAL27 cells were cultured in a serum-free medium in the upper chambers (Costar, Corning, NY). The upper chambers were placed into chambers containing BM or M1-CM. Then cells were treated following the protocol described in ref (39). For invasion assays, cells were seeded in matrigel-coated Transwell chambers (BD Biosciences, San Jose, CA) and then used for subsequent assays following a similar approach.

ELISA Assay

Supernatants from M0 macrophages, M1 macrophages, SCC25 cells, and CAL27 cells were collected and centrifuged at 12000 rpm at 4 °C for 10 min, and the concentrations of TNF-α, IL-6, and GDF15 were measured with ELISA kits (BOSTER).

RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction

Total RNA was isolated from cells with TRIzol reagent (Takara, Kusatsu, Japan) and then reverse-transcribed into cDNA with a PrimeScript RT reagent kit with gDNA Eraser (Takara) according to the instructions. Then quantitative real-time PCR assays were performed using the PCR System (Roche, Basel, Switzerland) with SYBR Green (Takara) to examine the mRNA of CD80, CD86, TNF-α, and IL-6 (in M1 macrophages) or ErbB2 and GDF15 (in tumor cells). The primers are listed in Table .
Table 1

Primers Sequences for Quantitative Real-Time PCR (qRT-PCR)

 primer sequences
gene5′–3′ forward5′–3′ reverse
GAPDHGGGAGCCAAAAGGGTCATGAGTCCTTCCACGATACCAA
CD80GCAGGG AACATCACCATCCATCACGTGGATAACACCTGAACA
CD86GGACTAGCACAGACACACGGACTTCAGAGGAGCAGCACCAGA
TNF-αGAGGCCAAGCCCTGGTATGCGGGCCGATTGATCTCAGC
IL-6ATCTGGATTCAATGAGGAGATCTGGCTTGTTCCTCACTAC
ErbB2GACAACCTCTATTACTGGGAGGCTTCTGCGGACTTGGCCT
GDF15CCTGAGACACCCGATTCCTACAGTTCCATCAGACCAGCC
CD163TCTCTTGGAGGAACAGACAAGGCCTGCACTGGAATTAGCCCA
CD206GATTGCAGGGGGCTTATGGGCGGACATTTGGGTTCGGGAG

Western Blotting

Total protein was extracted and concentrated by BCA protein assay as described by the manufacturer. Western blotting was carried out to detect the expression of CD80, CD86, GDF15, and phosphorylation activity of ErbB2, AKT, and ErK following the protocol described in ref (40). The antibodies are listed in Table .
Table 2

Primary Antibodies and Dilution Ratio for Western Blotting

antibodyproduct informationdilution ration
rabbit anti-CD86Cell Signaling Technology, Danvers, MA1:1000
rabbit anti-CD80Cell Signaling Technology, Danvers, MA1:1000
rabbit anti-ErbB2Abcam, Cambridge, UK1:1000
rabbit antiphospho-ErbB2Abcam, Cambridge, UK1:1000
rabbit anti-AKTCell Signaling Technology, Danvers, MA1:1000
rabbit antiphospho-AKTCell Signaling Technology, Danvers, MA1:1000
rabbit anti-ErK1/2Cell Signaling Technology, Danvers, MA1:1000
rabbit antiphospho-ErK1/2Cell Signaling Technology, Danvers, MA1:1000
rabbit anti-GDF15Abcam, Cambridge, UK1:1000
β-actinProteintech, Rocky Hill, NJ1:3000
α-tubulinProteintech, Rocky Hill, NJ1:10000
GAPDHProteintech, Rocky Hill, NJ1:20000

Tumor Xenograft Assay

For in vivo assays, 12 5-week-old BALB/C nude mice were randomized into a SCC25 group and a M1-CM-stimulated SCC25 group of six mice each. 1.5 × 107 cells were subcutaneously injected into the right axilla. The formula V = 0.5 × length × width × width was used to calculate tumor volume every 4 days. On the 35th day after injection, all mice were sacrificed and tumor tissue samples were dissected for further studies.

Immunohistochemistry Assay for Ki67 Expression

The immunohistochemistry of Ki67 was carried out as described in ref (38). Anti-Ki67 antibody was used at a dilution of 1:2000, and then goat antirabbit secondary antibody was used. Immunoreactions were detected with diaminobenzidine (DAB; Solarbio). Images were captured and the Ki67-positive cells were counted.

Statistical Analysis

Data were displaced as mean ± standard deviation (SD). One-way ANOVA followed by Tukey’s and two-way ANOVA followed by Sidak’s multiple comparisons tests were performed with GraphPad Prism software (version 8, by MacKiev Software, Boston, MA, USA). p < 0.05 was indicated a statistically significant difference.
  40 in total

1.  Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis.

Authors:  Ole Helm; Janka Held-Feindt; Evelin Grage-Griebenow; Norbert Reiling; Hendrik Ungefroren; Ilka Vogel; Uwe Krüger; Thomas Becker; Michael Ebsen; Christoph Röcken; Dieter Kabelitz; Heiner Schäfer; Susanne Sebens
Journal:  Int J Cancer       Date:  2014-02-05       Impact factor: 7.396

2.  Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.

Authors:  Jayashree P Joshi; Nicole E Brown; Samantha E Griner; Rita Nahta
Journal:  Biochem Pharmacol       Date:  2011-07-23       Impact factor: 5.858

3.  Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis.

Authors:  Liang Guo; Xiang Cheng; Hongyu Chen; Changguo Chen; Shuai Xie; Min Zhao; Dan Liu; Que Deng; Yanjun Liu; Xiaomeng Wang; Xintian Chen; Jiangong Wang; Zhaoyang Yin; Siyong Qi; Jiangping Gao; Yuanfang Ma; Ning Guo; Ming Shi
Journal:  Cancer Lett       Date:  2019-03-24       Impact factor: 8.679

4.  The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.

Authors:  Luís Lima; Daniela Oliveira; Ana Tavares; Teresina Amaro; Ricardo Cruz; Maria J Oliveira; José A Ferreira; Lúcio Santos
Journal:  Urol Oncol       Date:  2013-11-16       Impact factor: 3.498

Review 5.  Dual role of macrophage in tumor immunity.

Authors:  Ryota Tamura; Toshihide Tanaka; Yohei Yamamoto; Yasuharu Akasaki; Hikaru Sasaki
Journal:  Immunotherapy       Date:  2018-08       Impact factor: 4.196

6.  FAS and ErbB2 expression in early local recurrent oral cancer.

Authors:  L S S Pinto; F C A de Aguiar; L P Kowalski; E Graner; M A Lopes
Journal:  J Oral Pathol Med       Date:  2009-08-18       Impact factor: 4.253

Review 7.  Macrophage polarization in tumour progression.

Authors:  Antonio Sica; Paola Larghi; Alessandra Mancino; Luca Rubino; Chiara Porta; Maria Grazia Totaro; Monica Rimoldi; Subhra Kumar Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

8.  Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.

Authors:  Tong-Chao Zhao; Zhi-Hang Zhou; Wu-Tong Ju; Si-Yuan Liang; Xiao Tang; Dong-Wang Zhu; Zhi-Yuan Zhang; Lai-Ping Zhong
Journal:  Cancer Sci       Date:  2021-12-20       Impact factor: 6.716

9.  A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement.

Authors:  Amelia Chiara Trombetta; Stefano Soldano; Paola Contini; Veronica Tomatis; Barbara Ruaro; Sabrina Paolino; Renata Brizzolara; Paola Montagna; Alberto Sulli; Carmen Pizzorni; Vanessa Smith; Maurizio Cutolo
Journal:  Respir Res       Date:  2018-09-24

10.  M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.

Authors:  Zhaoyun Zong; Jiahuan Zou; Rudi Mao; Chao Ma; Na Li; Jianing Wang; Xiaoyan Wang; Huaiyu Zhou; Lining Zhang; Yongyu Shi
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

View more
  1 in total

Review 1.  Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer.

Authors:  Wei-Chiao Chiu; Da-Liang Ou; Ching-Ting Tan
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.